Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer (NCT05074589) | Jiangsu HengRui Medicine Co., Ltd. | 2018-01-25 |
Track Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy automatically
Every clearance here is in the API, with alerts when new ones post.